Unknown

Dataset Information

0

Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.


ABSTRACT: The ?-opioid receptor (DOP) is an attractive pharmacological target due to its potent analgesic, anxiolytic and anti-depressant activity in chronic pain models. However, some but not all selective DOP agonists also produce severe adverse effects such as seizures. Thus, the development of novel agonists requires a profound understanding of their effects on DOP phosphorylation, post-activation signaling and dephosphorylation. Here we show that agonist-induced DOP phosphorylation at threonine 361 (T361) and serine 363 (S363) proceeds with a temporal hierarchy, with S363 as primary site of phosphorylation. This phosphorylation is mediated by G protein-coupled receptor kinases 2 and 3 (GRK2/3) followed by DOP endocytosis and desensitization. DOP dephosphorylation occurs within minutes and is predominantly mediated by protein phosphatases (PP) 1? and 1?. A comparison of structurally diverse DOP agonists and clinically used opioids demonstrated high correlation between G protein-dependent signaling efficacies and receptor internalization. In vivo, DOP agonists induce receptor phosphorylation in a dose-dependent and agonist-selective manner that could be blocked by naltrexone in DOP-eGFP mice. Together, our studies provide novel tools and insights for ligand-activated DOP signaling in vitro and in vivo and suggest that DOP agonist efficacies may determine receptor post-activation signaling.

SUBMITTER: Mann A 

PROVIDER: S-EPMC7244497 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies.

Mann Anika A   Liebetrau Sophia S   Klima Marie M   Dasgupta Pooja P   Massotte Dominique D   Schulz Stefan S  

Scientific reports 20200522 1


The δ-opioid receptor (DOP) is an attractive pharmacological target due to its potent analgesic, anxiolytic and anti-depressant activity in chronic pain models. However, some but not all selective DOP agonists also produce severe adverse effects such as seizures. Thus, the development of novel agonists requires a profound understanding of their effects on DOP phosphorylation, post-activation signaling and dephosphorylation. Here we show that agonist-induced DOP phosphorylation at threonine 361 (  ...[more]

Similar Datasets

| S-EPMC3174411 | biostudies-literature
| S-EPMC2788680 | biostudies-literature
| S-EPMC10105690 | biostudies-literature
| S-EPMC7573615 | biostudies-literature
| S-EPMC5943185 | biostudies-literature
| S-EPMC2597450 | biostudies-literature
| S-EPMC5978946 | biostudies-literature
| S-EPMC3952808 | biostudies-literature
| S-EPMC3154617 | biostudies-literature
| S-EPMC8344368 | biostudies-literature